Innate Pharma SA 6-K, filed Mar 3, 2022
Innate Pharma SA (IPHA)
About this 6-K
Innate Pharma SA filed this 6-K on March 3, 2022.
| Exhibit |
Description
|
|
|
|
| 99.1 | [Press Release dated March 3, 2022] |
|
|
INNATE PHARMA S.A. | |
|
|
|
|
| Date: March 3, 2022 | By: | /s/ MONDHER MAHJOUBI |
|
|
Name: | Mondher Mahjoubi |
|
|
Title: |
Chairman of the Executive Board and Chief Executive Officer
|
| Exhibit 99.1 |
Number of Shares and Voting Rights of Innate Pharma as of March 1, 2022
MARSEILLE, France--(BUSINESS WIRE)--March 3, 2022--Regulatory News:
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at March 1, 2022:
|
Total number of shares outstanding: |
79,728,657 ordinary shares |
|
|
|
6,514 Preferred Shares 2016 |
|
|
7,581 Preferred Shares 2017 |
||
|
Total number of theoretical voting rights (1): |
80,486,497 |
|
|
Total number of exercisable voting rights (2): |
80,467,922 |
| (1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016 (2016 Preferred Shares), i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. |
| (2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007. |
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:
|
ISIN code |
FR0010331421 |
|
|
Ticker code |
Euronext: IPH Nasdaq: IPHA |
|
|
LEI |
9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2020, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Contacts
For additional information, please contact:
Investors and Media
Innate Pharma
Henry Wheeler
Tel.: +33 761 88 38 74
Henry.wheeler@innate-pharma.fr
ATCG Press
Marie Puvieux (France)
Tel.: +33 (0)9 81 87 46 72
innate-pharma@atcg-partners.com